{"id":236398,"date":"2024-02-01T13:28:28","date_gmt":"2024-02-01T12:28:28","guid":{"rendered":"https:\/\/fefac.cat\/empresarial\/?p=236398"},"modified":"2024-02-01T13:29:20","modified_gmt":"2024-02-01T12:29:20","slug":"informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/","title":{"rendered":"Nou informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic"},"content":{"rendered":"\n

El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor musculoesquel\u00e8tic<\/h2>\n\n\n\n

El tractament del dolor musculoesquel\u00e8tic<\/strong> en les farm\u00e0cies comunit\u00e0ries s’explora en un informe de la FIP<\/a><\/span><\/em><\/strong>. La junta, que va reunir farmac\u00e8utics comunitaris, experts en pol\u00edtiques i investigadors, ha discutit els enfocaments farmacol\u00f2gics (analg\u00e8sics, antiinflamatoris no esteroides i relaxants musculars) i no farmacol\u00f2gics (dispositius de ter\u00e0pia premuda de curta durada i ter\u00e0pia de calor i fred) per a l’alleujament dels s\u00edmptomes en pacients amb dolors musculars i articulars. L’informe comparteix punts de vista sobre les barreres, la capacitaci\u00f3 i els recursos necessaris perqu\u00e8 els farmac\u00e8utics gui\u00efn l’autocura d’aquest tipus de dolor<\/strong>.<\/p>\n\n\n\n

El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor musculoesquel\u00e8tic <\/strong>. S’esmenta que el dolor d’esquena \u00e9s comuna en totes les edats, relacionant-se sovint amb estils de vida sedentaris i activitats prolongades<\/strong>, com l’\u00fas de computadores. Els farmac\u00e8utics poden oferir informaci\u00f3 sobre la gesti\u00f3 i pron\u00f2stic del dolor<\/strong>, capacitant als pacients en canvis d’estil de vida i millorant l’adher\u00e8ncia als tractaments.<\/p>\n\n\n\n

El dolor musculoesquel\u00e8tic abasta condicions agudes i cr\u00f2niques, associades amb esdeveniments com a caigudes, esquin\u00e7os i lesions esportives (agudes) o amb malalties espec\u00edfiques com a artrosis, artritis o fibromi\u00e0lgia. Se subratlla la import\u00e0ncia dels farmac\u00e8utics per educar sobre el maneig del pes, t\u00e8cniques posturals i altres enfocaments no farmacol\u00f2gics per a millorar el benestar musculoesquel\u00e8tic<\/strong>.<\/p>\n\n\n\n

El maneig d’aquest dolor implica enfocaments farmacol\u00f2gics<\/strong> (analg\u00e8sics, antiinflamatoris, relaxants musculars) i no farmacol\u00f2gics<\/strong>, incloent-hi ter\u00e0pies t\u00e8rmiques. Malgrat els beneficis de la ter\u00e0pia t\u00e8rmica, es destaca la falta d’educaci\u00f3 i suport que limita la capacitat dels farmac\u00e8utics per a recomanar-la. Les barreres inclouen la falta de capacitaci\u00f3 especialitzada, vies de refer\u00e8ncia adequades i col\u00b7laboraci\u00f3 interprofessional.<\/strong><\/p>\n\n\n\n

Es proposen iniciatives com la formaci\u00f3 integral, guies cl\u00edniques, habilitats de comunicaci\u00f3, recursos d’assessorament i estudis de casos per a fer costat als farmac\u00e8utics. <\/strong>L’aprenentatge continu i mantenir-se informat sobre avan\u00e7os s\u00f3n essencials, igual que un entorn de suport per a la col\u00b7laboraci\u00f3 i l’intercanvi de coneixements. <\/p>\n\n\n\n

Font: FIP<\/p>\n","protected":false},"excerpt":{"rendered":"

El tractament del dolor musculoesquel\u00e8tic en les farm\u00e0cies comunit\u00e0ries s’explora avui en un informe d’un panell d’informaci\u00f3 de la FIP. La junta, que va reunir farmac\u00e8utics comunitaris, experts en pol\u00edtiques i investigadors, va discutir els enfocaments farmacol\u00f2gics (analg\u00e8sics, antiinflamatoris no esteroides i relaxants musculars) i no farmacol\u00f2gics (dispositius de ter\u00e0pia premuda de curta durada i ter\u00e0pia de calor i fred) per a l’alleujament dels s\u00edmptomes en pacients amb dolors musculars i articulars.<\/p>\n","protected":false},"author":5,"featured_media":236400,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"\n

Dimarts, 13 de juny, a les 14.00 h<\/h2>\n\n\n\n

Est\u00e0 previst realitzar, el pr\u00f2xim 13 de juny, a les 14.00 hores, una jornada amb els Mossos d'Esquadra en format ONLINE,<\/span><\/strong> dirigida a socis de la FEFAC de Barcelona, Lleida, Tarragona i Girona. Si ets soci i est\u00e0s interessat a assistir, posa't en contacte amb mruiz@fefac.cat<\/strong>.<\/p>\n\n\n\n

Aquesta \u00e9s la segona sessi\u00f3 que s'organitza amb els Mossos d'Esquadra per part de la FEFAC. La primera va tenir lloc el 13 d'abril a la seu de PIMEC a Barcelona. <\/strong><\/p>\n\n\n\n

En primer lloc, es va recordar l'acord que la FEFAC <\/strong>va iniciar l'any 2021 amb el cos policial per refor\u00e7ar la seguretat a les farm\u00e0cies<\/strong>, aix\u00ed com del sistema de den\u00fancia amb cita pr\u00e8via.<\/p>\n\n\n\n

Durant la sessi\u00f3, tamb\u00e9 es va parlar del pla d'acci\u00f3 contra les viol\u00e8ncies sexuals <\/strong>(de g\u00e8nere, dom\u00e8stica i discriminaci\u00f3).<\/p>\n\n\n\n

Finalment, es van abordar les principals estafes relacionades amb l'\u00fas de les noves tecnologies<\/strong> aplicades a l'oficina de farm\u00e0cia i els ciberdelinq\u00fcents<\/strong>.<\/p>\n","_et_gb_content_width":"","footnotes":""},"categories":[2066,10,11,12,13,14,15,110,297],"tags":[711,2630,2631],"class_list":["post-236398","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-categoria-actualitat","category-empresarials","category-fefac","category-afb","category-afet","category-afell","category-agfe","category-informes","category-fefac-actua","tag-farmaceutics","tag-informe-fib","tag-dolor-musculoesqueletic"],"yoast_head":"\nL'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic<\/title>\n<meta name=\"description\" content=\"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic\" \/>\n<meta property=\"og:description\" content=\"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-01T12:28:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-01T12:29:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lgallardo@fefac.cat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"lgallardo@fefac.cat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/\"},\"author\":{\"name\":\"lgallardo@fefac.cat\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\"},\"headline\":\"Nou informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic\",\"datePublished\":\"2024-02-01T12:28:28+00:00\",\"dateModified\":\"2024-02-01T12:29:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/\"},\"wordCount\":412,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg\",\"keywords\":[\"farmac\u00e8utics\",\"informe FIB\",\"dolor musculoesquel\u00e8tic\"],\"articleSection\":[\"Actualitat\",\"Empresarials\",\"FEFAC\",\"AFB\",\"AFET\",\"AFELL\",\"AGFE\",\"Informes\",\"FEFAC Actua\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/\",\"name\":\"L'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg\",\"datePublished\":\"2024-02-01T12:28:28+00:00\",\"dateModified\":\"2024-02-01T12:29:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\"},\"description\":\"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nou informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d'Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\",\"name\":\"lgallardo@fefac.cat\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/lucia-2\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic","description":"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/","og_locale":"ca_ES","og_type":"article","og_title":"L'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic","og_description":"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.","og_url":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/","og_site_name":"FEFAC","article_published_time":"2024-02-01T12:28:28+00:00","article_modified_time":"2024-02-01T12:29:20+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg","type":"image\/jpeg"}],"author":"lgallardo@fefac.cat","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"lgallardo@fefac.cat","Temps estimat de lectura":"3 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/"},"author":{"name":"lgallardo@fefac.cat","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9"},"headline":"Nou informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic","datePublished":"2024-02-01T12:28:28+00:00","dateModified":"2024-02-01T12:29:20+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/"},"wordCount":412,"commentCount":0,"image":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg","keywords":["farmac\u00e8utics","informe FIB","dolor musculoesquel\u00e8tic"],"articleSection":["Actualitat","Empresarials","FEFAC","AFB","AFET","AFELL","AGFE","Informes","FEFAC Actua"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/","url":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/","name":"L'informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#primaryimage"},"image":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg","datePublished":"2024-02-01T12:28:28+00:00","dateModified":"2024-02-01T12:29:20+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9"},"description":"El text destaca el paper cr\u00edtic dels farmac\u00e8utics comunitaris en la gesti\u00f3 integral del dolor.","breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#primaryimage","url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg","contentUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/02\/hombre-que-experimenta-dolor-cuello-mientras-trabaja-casa-computadora-portatil-scaled.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/informe-fip-sobre-el-paper-del-farmaceutic-en-el-tractament-del-dolor-musculoesqueletic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"Nou informe de la FIP sobre el paper del farmac\u00e8utic en el tractament del dolor musculoesquel\u00e8tic"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d'Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9","name":"lgallardo@fefac.cat","url":"https:\/\/fefac.cat\/empresarial\/author\/lucia-2\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/236398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=236398"}],"version-history":[{"count":0,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/236398\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media\/236400"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=236398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=236398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=236398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}